Immunogenicity and tolerability of COVID-19 vaccination in peritoneal dialysis patients-A prospective observational cohort study

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Haase, M (Author) Other; Lesny, P (Author) Other; Haase Fielitz, A (Author) Other; Anderson, M (Author) Other; Cloherty, G (Author) Other; Stec, M (Author) Other; Lucas, C (Author) Other; Santos-Araújo C (Author) FMUP; Haarhaus, M (Author) Other; Macario, F (Author) Other

Journal

Title: Seminars in Dialysis

Vol. 35

Pages: 269-277

ISSN: 0894-0959

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 3 Citations

Other information

Authenticus ID: P-00V-RZR

DOI: 10.1111/sdi.13043

Abstract (EN): Background In peritoneal dialysis (PD) patients, information on the immunogenicity and tolerability of SARS-CoV-2 vaccination is still scarce. We compared the immunogenicity and tolerability of SARS-CoV-2 vaccination of PD patients with that of medical personnel. Methods In a prospective observational cohort study, PD patients and immunocompetent medical personnel were evaluated for SARS-CoV-2 spike-IgG- and Nucleocapsid-IgG-antibody-levels before, 2 weeks after the first, and 6 weeks after the second SARS-CoV-2 vaccination and vaccine tolerability after the first and second vaccination. Results In COVID-19-naive PD patients (N = 19), lower SARS-CoV-2-spike-IgG-levels were found compared with COVID-19-naive medical personnel (N = 24) 6 weeks after second vaccination (median 1438 AU/ml [25th-75th percentile 775-5261] versus 4577 [1529-9871]; p = 0.045). This finding resulted in a lower rate of strong vaccine response (spike-IgG >= 1000 AU/ml) of COVID-19-naive PD patients compared with medical personnel (58% versus 92%; p = 0.013), but not for seroconversion rate (spike-IgG >= 50 AU/ml: 100% vs. 100%; p > 0.99). After first vaccination, COVID-naive PD patients presented with significantly fewer side effects than medical personnel (number of any side effect: 1 [1-2] vs. 4 [1-7]; p = 0.015). A similar pattern with slightly decreased frequencies of side effects was observed for tolerability of second SARS-CoV-2 vaccination in PD patients and medical personnel (number of any side effects: 1 [1-1] vs. 2 [1-5]; p = 0.006). Conclusions SARS-CoV-2 vaccination in COVID-19-naive PD patients appeared to induce a very high rate of seroconversion but a substantially lower rate of patients with a strong response compared with medical personnel. Vaccination appeared to be safe in the PD patients studied.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 9